Gsa Capital Partners LLP Novo Cure LTD Transaction History

Gsa Capital Partners LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$56.44 - $118.81 $197,427 - $415,597	3,498 New	3,498 $210,000
Q2 2022 Aug 09, 2022	BUY	$56.6 - $89.9 $478,949 - $760,733	8,462 New	8,462 $588,000
Q4 2020 Feb 03, 2021	SELL	$112.16 - $174.14 $244,620 - $379,799	-2,181 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$58.05 - $111.31 $126,607 - $242,767	2,181 New	2,181 $243,000
Q1 2020 May 12, 2020	SELL	$57.05 - $95.75 $136,920 - $229,800	-2,400 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$68.3 - $93.8 $131,136 - $180,096	-1,920 Reduced 44.44%	2,400 $202,000
Q3 2019 Nov 12, 2019	SELL	$61.86 - $97.8 $800,777 - $1.27 Million	-12,945 Reduced 74.98%	4,320 $323,000
Q2 2019 Aug 06, 2019	SELL	$42.22 - $63.23 $205,653 - $307,993	-4,871 Reduced 22.0%	17,265 $1.09 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $327,142 - $574,444	10,236 Added 86.02%	22,136 $1.07 Million
Q4 2018 Feb 12, 2019	SELL	$28.72 - $52.63 $496,856 - $910,499	-17,300 Reduced 59.25%	11,900 $398,000
Q3 2018 Nov 13, 2018	SELL	$32.0 - $52.4 $649,600 - $1.06 Million	-20,300 Reduced 41.01%	29,200 $1.53 Million
Q2 2018 Aug 09, 2018	BUY	$19.85 - $32.0 $577,635 - $931,200	29,100 Added 142.65%	49,500 $1.55 Million
Q1 2018 May 11, 2018	SELL	$19.3 - $23.65 $148,610 - $182,105	-7,700 Reduced 27.4%	20,400 $445,000
Q4 2017 Feb 14, 2018	BUY	$16.3 - $21.9 $65,200 - $87,600	4,000 Added 16.6%	28,100 $568,000
Q3 2017 Nov 20, 2017	BUY	$18.05 - $21.75 $435,005 - $524,175	24,100	24,100 $478,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.37B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.